Genix Pharmaceuticals Corporation
GENX.V
TSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -96.55% | -80.95% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -96.55% | -80.95% |
| Cost of Revenue | -- | -- | -- | 10,215.38% | 10,238.46% |
| Gross Profit | -- | -- | -- | -7,982.35% | -4,703.45% |
| SG&A Expenses | -33.73% | -32.93% | -32.96% | -33.25% | -24.22% |
| Depreciation & Amortization | -50.00% | -25.00% | 0.00% | -99.21% | -99.60% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -68.87% | -67.62% | -66.49% | -8.55% | -29.56% |
| Operating Income | 68.77% | 67.25% | 66.10% | 7.56% | 28.93% |
| Income Before Tax | -275.55% | -134.88% | -341.70% | 97.96% | 98.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -275.55% | -134.88% | -341.70% | 97.96% | 98.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -275.55% | -134.88% | -341.70% | 97.96% | 98.03% |
| EBIT | 68.77% | 67.25% | 66.10% | 7.56% | 28.93% |
| EBITDA | 81.80% | 73.47% | 66.30% | -47.16% | -63.34% |
| EPS Basic | -260.00% | -120.00% | -344.44% | 97.99% | 98.03% |
| Normalized Basic EPS | 48.84% | 56.52% | 44.19% | -2.38% | 12.24% |
| EPS Diluted | -260.00% | -120.00% | -344.44% | 97.99% | 98.03% |
| Normalized Diluted EPS | 48.84% | 56.52% | 44.19% | -2.38% | 12.24% |
| Average Basic Shares Outstanding | 2.23% | 1.38% | 0.54% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 2.23% | 1.38% | 0.54% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |